Clinical Trial

Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The objective of the study is to evaluate the safety, tolerability, pharmacokinetics, efficacy and biomarker of ONO-4578 and combinations of ONO-4578 and ONO-4538 in subjects with advanced or metastatic solid tumors and subjects with unresectable, advanced or recurrent gastric cancer, unresectable, advanced or recurrent colorectal cancer.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2017-05-15; most recent amendment 2025-06-04.
Status change: Recruiting → Active, Not Recruiting 2021-12-16
Trial Details
NCT Number NCT03155061
Lead Sponsor Ono Pharmaceutical Co., Ltd.
Conditions Advanced or Metastatic Solid Tumors
Enrollment 183 participants
Start Date 2017-04-19
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-06-05